NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $26.04, above its previous 52-week high of $25.95 with 114,186 shares traded as of 3:09 p.m. ET. Average volume has been 230,300 shares over the past 30 days.
Bio-Reference has a market cap of $704.3 million and is part of the
industry. Shares are up 56.4% year to date as of the close of trading on Monday.
Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. The company has a P/E ratio of 19.1, below the average health services industry P/E ratio of 19.3 and above the S&P 500 P/E ratio of 17.7.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
TheStreet Ratings rates Bio-Reference as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full
52-week high stocks
or get investment ideas from our